R Judd Jessup Sells 4,023 Shares of CorVel (NASDAQ:CRVL) Stock

CorVel Corp. (NASDAQ:CRVL) Director R Judd Jessup sold 4,023 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $70.07, for a total transaction of $281,891.61. Following the completion of the sale, the director owned 111,798 shares of the company’s stock, valued at $7,833,685.86. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

R Judd Jessup also recently made the following trade(s):

• On Thursday, August 27th, R Judd Jessup sold 1,262 shares of CorVel stock. The stock was sold at an average price of $70.64, for a total transaction of $89,147.68.
• On Wednesday, August 26th, R Judd Jessup sold 1,562 shares of CorVel stock. The stock was sold at an average price of $70.71, for a total transaction of $110,449.02.

CorVel Stock Performance

NASDAQ:CRVL traded down $1.65 during mid-day trading on Thursday, reaching $68.74. The stock had a trading volume of 132,975 shares, compared to its average volume of 217,747. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of 30.55 and a beta of 0.97. CorVel Corp. has a twelve month low of $44.83 and a twelve month high of $93.45. The business has a 50 day simple moving average of $64.01 and a 200 day simple moving average of $58.79.

CorVel (NASDAQ:CRVL) last announced its quarterly earnings data on Tuesday, August 4th. The business services provider reported $0.63 earnings per share for the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.72%.The company had revenue of $259.93 million for the quarter.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Weiss Ratings upgraded CorVel from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday. Wall Street Zen upgraded shares of CorVel from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CRVL. Corient Private Wealth LP lifted its position in shares of CorVel by 43.4% during the 2nd quarter. Corient Private Wealth LP now owns 50,913 shares of the business services provider’s stock valued at $3,183,000 after acquiring an additional 15,414 shares during the period. Amundi acquired a new stake in shares of CorVel in the 2nd quarter worth approximately $386,000. California State Teachers Retirement System grew its holdings in shares of CorVel by 7,962.8% in the 2nd quarter. California State Teachers Retirement System now owns 2,350,314 shares of the business services provider’s stock worth $146,942,000 after acquiring an additional 2,321,164 shares during the period. Nykredit A S purchased a new position in CorVel in the 2nd quarter valued at approximately $80,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in CorVel by 1.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 78,890 shares of the business services provider’s stock valued at $4,932,000 after purchasing an additional 1,116 shares in the last quarter. 51.36% of the stock is owned by hedge funds and other institutional investors.

CorVel Company Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).